Advertisement

Interferon Effect on Cytotoxicity of Autologous Stimulated Lymphocytes from Patients with Malignant Glioma

  • Koichi Miyagi
  • Jiro Mukawa
  • Hisashi Koga
  • Yasushi Higa
  • Susumu Nakasone
  • Susumu Mekaru
  • Marylou Ingram

Abstract

Itoh et al. [1] demonstrated that the rIL-2-induced activated killer (AK) activity of peripheral blood lymphocytes (PBLs) was augmented when treated by recombinant inteferon γ (rIFNγ), and that the lymphocytes were also promoted in proliferation. A human brain tumor cell line (allogeneic) was used as one of the target cells for AK assay in their study. However, there has been no study of its action against autologous tumor cells. Ellis et al. [2] reported that natural killer (NK) cells, when activated by either rIFNα or γ, acquired lymphokine-activated killer (LAK) cytolytic activity and lysed NK-resistant cells. Inteferon (IFN)-induced LAK cytotoxicity reached a peak value 24h after culture with IFNα (500 units/ml) and IFNγ (1000 units/ml). The question of whether or not IFN makes LAK cells cytotoxic against autologous glioma still remains unsolved. The present study was designed to elucidate this question.

Keywords

Natural Killer K562 Cell Cytolytic Activity Raji Cell Adoptive Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K (1985) Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-γ ( IFNγ ). J Immunol 134: 3124–3129PubMedGoogle Scholar
  2. 2.
    Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI (1989) Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 143: 4282–4286PubMedGoogle Scholar
  3. 3.
    Ingram M, Buckwalter JG, Jacques S, Freshwater DB, Abts RM, Techy G, Miyagi K, Sheldon H, Rand RW, English LW (1990) Immunotherapy for recurrent malignant glioma: An interim report on survival. Neurol Res 12: 265–273PubMedGoogle Scholar
  4. 4.
    Ingram M, Jacques S, Freshwater DB, Techy G, Sheldon H, Helsper JT (1987) Salvage immunotherapy of malignant glioma. Arch Surg 122: 1483–1486PubMedCrossRefGoogle Scholar
  5. 5.
    Kruse CA, Lillehei KO, Johnson SD, McCleary EL, Moor GE, Mitchell DH, Waldrop S, Mierau GW (1989). Two preparations of interleukin-2 activated lymphocytes used for adoptive immunotherapy of primary glioma. Cancer 64: 1629–1637PubMedCrossRefGoogle Scholar
  6. 6.
    Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon. J Exp Med 157: 884–897PubMedCrossRefGoogle Scholar
  7. 7.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) The lymphokine activated killer cell phenomenon: Lysis of NK resistant fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841PubMedCrossRefGoogle Scholar
  8. 8.
    Brooks C, Holschen M, Urdal D (1985) Natural killer activity in cloned cytotoxic T lymphocytes: Regulation by interleukin 2, interferon, and specific antigen. J Immunol 135: 1145–1152PubMedGoogle Scholar
  9. 9.
    Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH (1989) Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: Identification and isolation of effector subsets. Cancer Res 49: 963–968PubMedGoogle Scholar
  10. 10.
    Toledano M, Mathiot C, Michon J, Andreu G, Lando D, Brandely M, Fridman WH (1989) Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity—IFN-gamma-induced suppressive activity. Cancer Immunol Immunother 30: 57–64PubMedCrossRefGoogle Scholar
  11. 11.
    Sone S, Utsugi T, Nii A, Ogura T (1988) Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)- activated killer activity. Cancer Inst 80: 425–431CrossRefGoogle Scholar
  12. 12.
    Powell J, Stone J, Chan WC, Yang ZD, Leatherbury A, Sell KW, Wiktor-Jedrzejczak W, Ahmed-Ansari A (1989) Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer ( LAK) cells. Cell Immunol 118: 250–264PubMedCrossRefGoogle Scholar
  13. 13.
    Gronberg A, Ferm M, Tsai L, Kiessling R (1989) Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer ( LAK) cells. Cell Immunol 118: 10–21PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1991

Authors and Affiliations

  • Koichi Miyagi
    • 1
  • Jiro Mukawa
    • 1
  • Hisashi Koga
    • 1
  • Yasushi Higa
    • 1
  • Susumu Nakasone
    • 1
  • Susumu Mekaru
    • 1
  • Marylou Ingram
    • 2
  1. 1.Department of NeurosurgeryUniversity of the Ryukyus, School of MedicineOkinawaJapan
  2. 2.Experimental and Clinical Immunotherapy LaboratoryHuntington Medical Research Institutes (HMRI)PasadenaUSA

Personalised recommendations